1. ALA2094261 F MMV: Screen against Mtb, single point, non replicating, at 25uM Mycobacterium tuberculosis 399 organism-based format MMV Malaria Box 2. ALA2094262 F MMV: Screen against Mtb, single point, replicating, at 25uM Mycobacterium tuberculosis 399 organism-based format MMV Malaria Box 3. ALA2094263 F MMV: CRC and MIC90 against Mtb (non replicating) Mycobacterium tuberculosis 55 organism-based format MMV Malaria Box 4. ALA2094264 F MMV: CRC and MIC90 against Mtb (replicating) Mycobacterium tuberculosis 56 organism-based format MMV Malaria Box 5. ALA2094265 T MMV: Cytotoxicity CRC and LD50 against HepG2 Homo sapiens 57 cell-based format MMV Malaria Box 6. ALA2028070 F MMV: Inhibition of Plasmodium falciparum 3D7 at 5uM compound concentration. Plasmodium falciparum 315 organism-based format MMV Malaria Box 7. ALA2028071 F MMV: Inhibition of Plasmodium falciparum 3D7 (EC50). Plasmodium falciparum 317 organism-based format MMV Malaria Box 8. ALA2028072 F MMV: Inhibition of Plasmodium falciparum K1 (EC50). Plasmodium falciparum 171 organism-based format MMV Malaria Box 9. ALA2028073 F MMV: Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro). Trypanosoma cruzi 400 organism-based format MMV Malaria Box 10. ALA2028074 F MMV: Inhibition of Trypanosoma brucei brucei (Squib 427) (HAT in vitro). Trypanosoma brucei brucei 400 organism-based format MMV Malaria Box 11. ALA2028075 F MMV: Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro). Trypanosoma brucei rhodesiense 400 organism-based format MMV Malaria Box 12. ALA2028076 F MMV: Inhibition of Leishmania infantum (MHOM/MA/BE/67) in vitro. Leishmania infantum 400 organism-based format MMV Malaria Box 13. ALA2028077 T MMV: Cytotoxicity against human fibroblasts (MRC-5) cells. Homo sapiens 400 cell-based format MMV Malaria Box 14. ALA1040691 F NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay Plasmodium falciparum 5,614 organism-based format Novartis Malaria Screening 15. ALA1040692 F NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay Plasmodium falciparum 5,614 organism-based format Novartis Malaria Screening 16. ALA1040693 T NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) Homo sapiens 5,614 cell-based format Novartis Malaria Screening 17. ALA1040694 F NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. 5,614 assay format Novartis Malaria Screening 18. ALA1789905 F NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. Plasmodium yoelii 4,416 organism-based format Novartis Malaria Screening 19. ALA2363023 F MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 24 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF. Schistosoma mansoni 400 organism-based format MMV Malaria Box 20. ALA2363024 F MMV: Toxicity @ 2.5 uM to newly transformed Schistosoma mansoni somules after 48 h on a scale of 0 (none) - 4 (most) as judged visually: includes short descriptors of effects (PMID:19597541). Caffrey group UCSF. Schistosoma mansoni 400 organism-based format MMV Malaria Box